Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib
Phase I/II Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition of the Proteasome Inhibitor Ixazomib: Big Ten Cancer Research Consortium BTCRC-HEM17-092
Sponsor: H Scott Boswell
Terminated
Funder requested termination due to halting internal development of TAK-659
Listed as NCT04079738, this PHASE1/PHASE2 trial focuses on AML and AML, Adult and remains terminated or withdrawn. Sponsored by H Scott Boswell, it has been updated 10 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Apr 2022 — Oct 2023 [monthly]
Terminated PHASE1_PHASE2
Status: Active Not Recruiting → Terminated
-
Oct 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2019 — Dec 2020 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Oct 2019 — Nov 2019 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Sep 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- H Scott Boswell
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .